Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05979792
Other study ID # BHCT-RD13-02P
Secondary ID
Status Not yet recruiting
Phase Early Phase 1
First received
Last updated
Start date September 1, 2023
Est. completion date December 1, 2025

Study information

Verified date August 2023
Source Ruijin Hospital
Contact Weili Zhao, Doctor
Phone +862164370045
Email zwl_trial@163.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Despite the use of monoclonal antibodies, checkpoint inhibitors, and bispecific T cell adapters (BiTE) Immunotherapies such as chimeric antigen receptor (CAR) T cells have completely changed the treatment methods of various cancers. However, only limited responses were observed in T cell diseases, In CD30 positive PTCL and CTCL patients. The use of BV in and pembroluzimab (Programmed cell death receptor 1) in the treatment of ENKTL. Although some promising results have been observed for (PD-1) inhibitors, these positive results are limited to specific subtypes of T cell diseases. CAR T Cell therapy in recurrent/refractory B-cell malignant tumors is very successful, the Food and Drug Administration (FDA) has approved two CAR T Cell therapy for the treatment of this type of disease. However, using this technology to treat T-cell malignancies has always been difficult, mainly due to the lack of tumor specific surface antigens in cancerous T cells. Therefore, our center plans to conduct a phase I clinical study of CAR-T to explore the possibility of bringing more treatment options and benefits to PTCL patients.


Description:

Patients with recurrent/refractory PTCL were included using a single arm, open label, and single center approach. Pre treatment plan: Cyclophosphamide (CTX): 500mg/m2 × 3 days Fludarabine: 30mg/m2 × 3 days Note: Researchers can adjust the pre-treatment plan appropriately based on the patient's condition, such as CTX 300mg × Wait for 3 days. CTX and Flu were infused on the 5th to 3rd day (D-5 to D-3) before administration. RD13-02 can only be injected after 48 hours of pre-treatment.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 35
Est. completion date December 1, 2025
Est. primary completion date August 1, 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years to 79 Years
Eligibility Inclusion Criteria: 1. Age = 18 years old and<80 years old. 2. According to the clinical practice guidelines for T-cell lymphoma of the National Comprehensive Cancer Network (NCCN) (2022. v2), diagnosis of peripheral T-cell lymphoma, including but not limited to: peripheral T Cell lymphoma, non-specific type (PTCL-NOS), anaplastic large cell lymphoma (ALCL), T helper cell lymphoma (FTCL), peripheral lymph nodes with follicular helper T cell phenotype T-cell lymphoma (TFH) and angioimmunoblastic T-cell lymphoma (AITL), Etc; 3. Relapse or refractory peripheral T-cell lymphoma, which requires at least 2 systematic Sex therapy, is invalid or relapses. 4. Histologically confirmed as CD7 positive. 5. According to Lugano2014 standard, enhanced CT before enrollment should indicate at least one evaluable tumor lesion (with the longest diameter of the intranodal lesion>1.5cm and the longest diameter of the extranodal lesion>1.0cm), and PET/CT should show metabolic activity. 6. Blood routine neutrophil count = 1.0 during screening × 109/L; For individuals without bone marrow invasion, platelet count = 75 × 109/L, Hb = 80g/L; For individuals with bone marrow invasion, platelet count = 50 × 109/L, Hb = 60g/L (if the patient does not meet the screening requirements but meets the screening period requirements for re examination, they can be selected). 7. The average fluorescence intensity (MFI) of donor specific antibodies (DSA) at HLA sites of HLA antibody negative or anti RD13-02 cell derived donors is less than 2000. 8. Creatinine clearance rate>60ml/min (Cockcroft and Gault formula); For patients without liver invasion, serum total bilirubin = 1.5 times the upper limit of normal value, and serum ALT and AST = 3 times the upper limit of normal value range; For patients with liver invasion, serum total bilirubin = 3 times the upper limit of normal value, and serum ALT and AST = 5 times the upper limit of normal value range. 9. Echocardiography showed that left ventricular Ejection fraction (LVEF) = 50%. 10. Estimated survival time of over 3 months. 11. ECOG: 0-1. 12. Subjects or their Legal guardian voluntarily participate in the trial and sign the informed consent form. 13. For patients undergoing reinfusion, in addition to meeting the relevant conditions for reinfusion in the Design of experiments, it is required that there is no DLT event or dose reduction after the first infusion. 14. The first 6 subjects included at any dose level should be able to collect sufficient amounts of autologous hematopoietic stem cells for cryopreservation in advance; Subsequent subjects will be determined by the researcher whether to collect autologous hematopoietic stem cells for cryopreservation. Exclusion Criteria: 1. Primary cutaneous T-cell lymphoma, including mycosis fungoides (MF) and Sezary syndrome (SS); Enteropathy associated T-cell lymphoma (EATL), monotypic epitheliophagocytic intestinal T-cell lymphoma (MEITL), hepatosplenic T-cell lymphoma (HSTCL), extranodal NK/T-cell lymphoma, nasal type (EENKTCL) and primary central nervous system lymphoma and other types of T-cell leukemia/lymphoma. 2. Active central nervous system (CNS) invasion. 3. If anti-tumor treatment has been received before infusion, it should be excluded if any of the following conditions are met: - received small molecule Targeted therapy within 72 hours - Received systemic chemotherapy within 2 weeks (excluding pre-treatment) - Received radiation therapy within 4 weeks - When the time between the last monoclonal antibody infusion and those who have received monoclonal antibody treatment is less than 5 half-lives four weeks long or less (whichever is shorter) 4. Individuals with a history of allergies to any component in cellular products. 5. According to the New York Heart Association (NYHA) cardiac function grading standards, subjects with cardiac dysfunction classified as Class III or IV. 6. Myocardial infarction, cardiac angioplasty or stenting, unstable angina pectoris, or other serious heart disease clinically within 12 months of enrollment. 7. The electrocardiogram indicates that the QT interval is significantly prolonged, and the patient has serious heart disease such as serious arrhythmia in the past. 8. Previous history of craniocerebral trauma, Disorders of consciousness, epilepsy, cerebrovascular ischemia, cerebrovascular hemorrhagic disease, etc. 9. Uncontrolled severe active infections (excluding simple urinary tract infections and bacterial pharyngitis). 10. The subject has a history of other primary cancers, except for the following: 1. Non Melanoma cured by excision, such as skin Basal-cell carcinoma; 2. Carcinoma in situ of cervix, local prostate cancer, and ductal Carcinoma in situ with disease-free survival = 2 years after adequate treatment; 11. Subjects with autoimmune diseases requiring treatment or subjects requiring Immunosuppressive drug treatment; 12. Individuals with graft versus host disease (GvHD) and/or requiring immunosuppressive therapy. 13. Live vaccination within 4 weeks prior to screening. 14. The subject has a history of alcoholism, drug abuse, or mental illness. 15. Individuals with EBV DNA copy numbers greater than the upper limit of normal or positive for EBER; CMV copies greater than the upper limit of normal values; HBV or HCV DNA copy number>the upper limit of normal value, and active syphilis or AIDS and other virus infected persons. 16. Subjects who were receiving systemic Sex hormone treatment before screening and who were judged by the investigator to need long-term use of systemic Sex hormone during treatment (except for inhalation or local use). 17. Individuals who have participated in other clinical trials within the first 4 weeks of screening. 18. Pregnant and lactating women and subjects with Fertility who cannot take effective contraceptive measures (both men and women). 19. Any situation that the researcher believes may increase the risk of the subject or interfere with the test results.

Study Design


Intervention

Drug:
CAR-T Therapy
CAR-T cell infusion

Locations

Country Name City State
China West China Hospital Sichuan University Chengdu Sichuan
China The First Affiliated Hospital of USTC Hefei Anhui
China The 920th Hospital of the Joint Service Support Force of the People's Liberation Army Kunming Yunan
China Ruijin Hospital, Shanghai Jiao Tong University School of Medicine Shanghai
China The Affliliated Hospital of Northwest University Xi'an Shanxi
China The First Affliliated Hospital of Xiamen University Xiamen Fujian
China Henan Cancer Hospital Zhengzhou Henan
China The First Affliated Hospital of Zhengzhou University Zhengzhou Henan

Sponsors (1)

Lead Sponsor Collaborator
Zhao Weili

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Dose-limiting toxicity DLT Up to 2 years
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04526834 - Phase 1 Study of Autologous CD30.CAR-T in Relapsed or Refractory CD30 Positive Non-Hodgkin Lymphoma Phase 1
Recruiting NCT04390737 - Evaluate the Safety and Clinical Activity of HH2853 Phase 1/Phase 2
Recruiting NCT05559008 - A Umbrella Study in R/R PTCL Guided by Molecular Subtypes Phase 1/Phase 2
Recruiting NCT06083701 - Phase I/II Study of Linperlisib Plus Chidamide for R/R Peripheral T-cell Lymphoma: a Prospective, Multi-center Study Phase 1/Phase 2
Not yet recruiting NCT02856997 - Chidamide With ICE Regimen for Relapsed/Refractory Peripheral T Cell Lymphoma Phase 2
Recruiting NCT04083495 - CD30 CAR for Relapsed/Refractory CD30+ T Cell Lymphoma Phase 2
Recruiting NCT04984837 - Study of Lacutamab in Peripheral T-cell Lymphoma Phase 2
Recruiting NCT06072131 - To Evaluate Efficacy of Belinostat or Pralatrexate in Combination Against CHOP Alone in PTCL Phase 3
Completed NCT01716806 - A Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL) Phase 2
Terminated NCT03947255 - A Study of Retreatment With Brentuximab Vedotin in Subjects With Classic Hodgkin Lymphoma or CD30-expressing Peripheral T Cell Lymphoma Phase 2
Recruiting NCT04028440 - γδT Cells Immunotherapy in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma (NHL) Early Phase 1
Not yet recruiting NCT05923502 - (CHANT)Real World Study of Duvelisib in the Treatment of Non-Hodgkin's Lymphoma (NHL)
Recruiting NCT05883449 - Phase 2 Study of AFM13 in Combination With AB-101 in Subjects With R/R HL and CD30+ PTCL Phase 2
Recruiting NCT05377827 - Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients With CD7+ Hematologic Malignancies Phase 1
Active, not recruiting NCT03586999 - Nivolumab With Standard of Care Chemotherapy for Peripheral T Cell Lymphomas Phase 1/Phase 2
Recruiting NCT04489264 - The Role of Consolidative Autologous Stem Cell Transplantation After First-line Therapy in Peripheral T Cell Lymphoma
Recruiting NCT06151106 - Chidamide and Duvalisibon for the Treatment of Refractory/Relapsed Peripheral T-cell Lymphoma Phase 2
Recruiting NCT02753543 - Chidamide Plus Chemotherapy in the Treatment of Peripheral T-cell Lymphoma Phase 2
Not yet recruiting NCT06089941 - Circulating Tumor DNA Sequencing in Patients With Peripheral T-cell Lymphomas
Recruiting NCT06131801 - Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution